Clinical Drug Resistant PDX Models
An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. The development of targeted therapies for overcoming drug resistance represents an unmet medical need.
Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease.
To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has developed a panel of unique clinical resistance models derived from patients who have relapsed or developed resistance to current therapeutic regimens.
Clinical drug resistant PDX models
Related Content
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE